12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LB-100: Phase I started

Lixte began an open-label, U.S. Phase I trial to evaluate IV LB-100 given alone on days 1-3 of a 21-day cycle and...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >